Clinical Scorecard: Reevaluating Aspirin's Role in Primary Prevention: Addressing Existing Discrepancies
At a Glance
Category
Detail
Condition
Primary prevention of cardiovascular disease
Key Mechanisms
Aspirin reduces ischaemic events (MACE: death, myocardial infarction, stroke) but increases major bleeding risk; benefit-risk balance depends on baseline cardiovascular risk
Target Population
Adults with medium to high cardiovascular risk, including those without overt atherosclerosis but with calculated 10-year MACE risk >10-20%
Care Setting
Primary care and cardiology outpatient settings
Key Highlights
Aspirin benefit in primary prevention increases with baseline cardiovascular risk, while bleeding risk also increases but less steeply.
Aspirin may be considered in patients with calculated 10-year MACE risk exceeding 10-20%, even without overt atherosclerosis.
Shared decision-making is essential due to uncertainties and the need to balance aspirin use with lifestyle and other pharmacological preventive measures.
Guideline-Based Recommendations
Diagnosis
Calculate 10-year cardiovascular risk to guide aspirin use decisions.
Consider detection of asymptomatic atherosclerosis (carotid plaques, coronary calcium score) as a factor for aspirin consideration.
Management
Use aspirin in addition to lifestyle measures and adequate blood pressure and lipid control in medium- to high-risk patients.
Administer aspirin with or soon after meals to reduce bleeding risk.
Consider proton pump inhibitors to mitigate gastrointestinal bleeding risk.
Avoid concomitant use of non-steroidal anti-inflammatory drugs to minimize bleeding complications.
Monitoring & Follow-up
Monitor for signs of major bleeding, especially in older, frail, or comorbid patients.
Regularly reassess cardiovascular risk and bleeding risk to adjust aspirin therapy accordingly.
Risks
Increased risk of major bleeding events, which rises with cardiovascular risk but less steeply than ischaemic event reduction.
Uncertainties remain regarding benefit-risk ratio in older, frail, diabetic, or renal failure patients.
Patient & Prescribing Data
Patients without previous vascular events but with cardiovascular risk factors and calculated medium to high 10-year MACE risk
Aspirin's protective effect against ischaemic events becomes more favorable as baseline cardiovascular risk increases, with bleeding risk rising less steeply, supporting its use in selected primary prevention patients.
Clinical Best Practices
Engage in shared decision-making with patients, explaining benefits and risks of aspirin therapy.
Combine aspirin use with lifestyle modifications and optimal control of blood pressure and lipids.
Use risk calculators to identify patients likely to benefit from aspirin in primary prevention.
Implement strategies to minimize bleeding risk, including timing of aspirin intake and use of gastroprotective agents.
Avoid NSAIDs concomitantly to reduce bleeding complications.
